VM202

Phase 2Small molecule

HHelixmith Co., Ltd.

VM202 is one of 183 small molecule programs targeting Ischemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

182

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Heart DiseaseActive, not recruiting

GrowthActive, not recruiting

Diabetic NeuropathyActive, not recruiting

IschemiaPhase 1

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 1/Phase 2

Active, not recruiting

Heart DiseasePhase 1/Phase 2

Active, not recruiting

GrowthPhase 2

Active, not recruiting

Diabetic NeuropathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

VM202

HHelixmith Co., Ltd.

Phase 2

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Aricept

Eisai

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

EGRIFTA WR

2 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

Hepatocyte Growth Factor to Improve Functioning in PAD

Completed·NNorthwestern University·Phase 2·NCT03363165·39 enrolled

Diabetic Neuropathy1 trial

Gene Therapy for Painful Diabetic Neuropathy

Completed·HHelixmith Co., Ltd.·Phase 1/2·NCT01002235·12 enrolled

Amyotrophic Lateral Sclerosis1 trial

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

Completed·HHelixmith Co., Ltd.·Phase 1/2·NCT02039401·18 enrolled

Chronic Stable Angina1 trial

Gene Therapy for the Treatment of Chronic Stable Angina

Withdrawn·HHelixmith Co., Ltd.·Phase 1/2·NCT01002495

Heart Disease1 trial

Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

Completed·HHelixmith Co., Ltd.·Phase 1/2·NCT01422772·9 enrolled

1 more indication

Ischemia1 trial

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

Completed·HHelixmith Co., Ltd.·Phase 1·NCT00696124·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for VM202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VM202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VM202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Helixmith Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHelixmith Co., Ltd.

VM202

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Diabetic Neuropathy1 trial

Amyotrophic Lateral Sclerosis1 trial

Chronic Stable Angina1 trial

Heart Disease1 trial

Ischemia1 trial

References

Drug Info

Quick Facts

Related News